Literature DB >> 25607980

Nuclear-translocated endostatin downregulates hypoxia inducible factor-1α activation through interfering with Zn(II) homeostasis.

Lifang Guo1, Yang Chen2, Ting He2, Feifei Qi2, Guanghua Liu2, Yan Fu2, Chunming Rao3, Junzhi Wang3, Yongzhang Luo2.   

Abstract

Hypoxia‑inducible factor‑1α (HIF‑1α) is key in tumor progression and aggressiveness as it regulates a series of genes involved in angiogenesis and anaerobic metabolism. Previous studies have shown that the transcriptional levels of HIF‑1α may be downregulated by endostatin. However, the molecular mechanism by which endostatin represses HIF‑1α expression remains unknown. The current study investigated the mechanism by which nuclear‑translocated endostatin suppresses HIF‑1α activation by disrupting Zn(II) homeostasis. Endostatin was observed to downregulate HIF‑1α expression at mRNA and protein levels. Blockage of endostatin nuclear translocation by RNA interference of importin α1/β1 or ectopic expression of NLS‑deficient mutant nucleolin in human umbilical vein endothelial cells co‑transfected with small interfering (si)‑nucleolin siRNA compromises endostatin‑reduced HIF‑1α expression. Nuclear‑translocated apo‑endostatin, but not holo‑endostatin, significantly disrupts the interaction between CBP/p300 and HIF‑1α by disturbing Zn(II) homeostasis, which leads to the transcriptional inactivation of HIF‑1α. The results reveal mechanistic insights into the method by which nuclear‑translocated endostatin downregulates HIF‑1α activation and provides a novel way to investigate the function of endostatin in endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25607980     DOI: 10.3892/mmr.2015.3223

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  1 in total

1.  Wnt3a promotes pro-angiogenic features in macrophages in vitro: Implications for stroke pathology.

Authors:  Almudena Fuster-Matanzo; Giulia Manferrari; Bianca Marchetti; Stefano Pluchino
Journal:  Exp Biol Med (Maywood)       Date:  2017-12-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.